Here is the foundational math
Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
Activating these receptors modulates mood, movement, appetite, pain and sensation, memory, and perception
Heres why Southlakeites pick to Semaglutide suppresses appetite for semaglutide real results: Biology over willpower Fad diets like keto ignore hormonal hunger signals
The researchers reported that liraglutide alone had similar effectiveness to metformin alone for managing PCOS symptoms
Laddha, N